Skip to content
Forty-five years ago, the Bayh-Dole Act enabled greater public-private partnership, supercharging U.S. innovation and helping make America a leader in biotech. The Bayh-Dole Coalition […]
Bayh-Dole Coalition promotes a law that supercharged innovation Read More »
A group led by the Biotechnology Innovation Organization (BIO) will recommend new international guidelines for manufacturers of cell and gene therapies (CGT) to support
BIO group to suggest global guidelines for regulating cell and gene therapies Read More »
Lawmakers questioned Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. on key issues like vaccines, biosecurity, and federal research funds in a
Lawmakers question Kennedy on vaccines, biosecurity, and NIH cuts Read More »
Legislation to encourage rare disease drug development, enable tax deductions for research, and put checks on middlemen who drive up drug prices moved forward
House advances legislation on PBM reform, orphan drug support, R&D deductions Read More »
Tariffs on pharmaceuticals would harm supply chains that ensure we have enough medicines while threatening America’s security, economy, and biotech leadership, the Biotechnology Innovation
BIO’s comments on tariffs: There are better ways to strengthen U.S. biotech Read More »
The May 1 reintroduction of two bills designed to strengthen the certainty of U.S. patents earned praise from the Biotechnology Innovation Organization (BIO). The
BIO applauds reintroduction of two bills aimed at patent reform Read More »
Given the importance of intellectual property for biotech, the Biotechnology Innovation Organization (BIO) remains vigilant in ensuring IP is protected. In recognition of World
BIO IP expert reviews the current policy landscape Read More »
A trade war will harm American growers and the biotech firms who help them increase productivity, according to the Biotechnology Innovation Organization (BIO). President
Tariffs hurt growers and ag biotech, BIO says Read More »
Maintaining biotechnology superiority is essential to the U.S. economy and national security, and it must be supported with strategic federal funding that leans into
Congressional commission urges support in U.S.-China competition for biotech dominance Read More »
We need policy to improve patient access to drugs and address middlemen who increase drug prices, according to participants in a March 27 healthcare
Summit on health care’s future shines light on PBM abuses Read More »
